DIFFUSION PHARMACEUTICALS INC. (NASDAQ:DFFN) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders

A Special Meeting of Stockholders (the Special Meeting) of
Diffusion Pharmaceuticals Inc. (the Company) was held on January
6, 2017. A quorum was present at the Special Meeting. Matters
submitted to the stockholders and voted upon at the Special
Meeting, which are more fully described in the Companys Proxy
Statement filed with the Securities and Exchange Commission on
December 8, 2016 (the Proxy Statement), were: (1) to approve the
proposed terms of an offering, which contemplates the issuance
and sale (the Offering) of (i) shares of the Companys Series A
preferred stock, $0.001 par value per share (Preferred Stock),
each share of Preferred Stock being convertible into a share of
the Companys common stock, par value $0.001 per share (Common
Stock), subject to adjustment, (ii) for each share of Preferred
Stock purchased in this Offering, a 5-year warrant to purchase
one share of Common Stock (the Warrants), and (iii) such number
of shares of Common Stock issuable upon conversion of the
Preferred Stock and upon exercise of Warrants, including without
limitation shares issuable to the make-whole and anti-dilution
provisions of the Preferred Stock, exceeding 19.9% of our
outstanding Common Stock (collectively, the Offering Proposal);
(2) to approve an amendment to the Companys Certificate of
Incorporation, as amended, to increase the authorized number of
shares of preferred stock from 5,000,000 to 30,000,000 (the
Charter Amendment); and (3) to approve an adjournment of the
Special Meeting, if necessary, to solicit additional proxies if
there are not sufficient votes in favor of the Offering Proposal.
At the Special Meeting, the Companys stockholders approved the
three proposals, and the final results were as follows:

About DIFFUSION PHARMACEUTICALS INC. (NASDAQ:DFFN)

Diffusion Pharmaceuticals Inc., formerly RestorGenex Corporation, is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company’s lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC) is used in various cancer types, in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments. The Company’s Diffusion’s technology is targeted at overcoming treatment-resistance in solid cancerous tumors by combining its lead product candidate, TSC, with standard-of-care radiation and chemotherapy regimens, thus effecting a better patient survival outcome without the addition of harmful side effects. Its clinical development plan targets TSC at the radiation and chemotherapy sensitization of hypoxic tumor types, with an initial focus on primary brain cancer (glioblastoma or GBM), pancreatic cancer, and brain metastases.

DIFFUSION PHARMACEUTICALS INC. (NASDAQ:DFFN) Recent Trading Information

DIFFUSION PHARMACEUTICALS INC. (NASDAQ:DFFN) closed its last trading session up +3.64 at 5.70 with 152 shares trading hands.